



**CANCER CENTER**

At the Detroit Medical Center

December 16, 2020

U.S. Nuclear Regulatory Commission, Region III  
Materials Licensing Branch  
2443 Warrenville Road, Suite 210  
Lisle, IL 60532-4352

Re: RSO change, NRC License #21-03298-06

Dear Reviewer,

We would like to request a transfer of the RSO position on license #21-03298-06 from Thomas J. Mangner, Ph.D. to Joseph T. Rakowski, Ph.D., effective March 1, 2021. Dr. Mangner will be retiring.

Joe Rakowski is the current RSO for our other license at this location, #21-04126-06, which includes any byproduct material permitted by 10 CFR 35.100 and 10 CFR 35.200. Documentation of his previous license RSO experience with those categories is attached.


If you require further assistance please feel free to contact our RSO Joe Rakowski at (313) 576-9616.

Thank you.

Sincerely,

Mara Jelich  
Executive Director, Radiation Oncology and Imaging  
Karmanos Cancer Center  
4100 John R St., Mail Code GE00RO  
Detroit, MI 48201

1 Attachment  
Flower Hospital  
License dated  
12/1/2003



RECEIVED JAN 05 2021

## OHIO DEPARTMENT OF HEALTH LICENSE FOR RADIOACTIVE MATERIAL

Pursuant to Chapter 3748 of the Ohio Revised Code, and in reliance on statements and representations made by the licensee, a license is hereby issued authorizing the licensee named herein to receive, acquire, possess, and transfer radioactive material as designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the applications of Chapter 3748 of the Ohio Revised Code and all applicable rules promulgated thereunder. This license is subject to all applicable rules, regulations and orders of the Ohio Department of Health now or hereinafter in effect and to any conditions specified below.

LICENSEE  1. Flower Hospital  2. 5200 Harroun Road Sylvania, Ohio 43560-2196	LICENSE NUMBER 3. 02120490004  EXPIRATION DATE 4. July 31, 2003  BUREAU DOCKET NUMBER 5. DC/CJC51-12-97
---	--

6. RADIOACTIVE MATERIAL	7. CHEMICAL AND/OR PHYSICAL FORM	8. MAXIMUM QUANTITY THAT LICENSEE MAY POSSESS AT ANY ONE TIME UNDER THIS LICENSE
A. Any radioactive material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed. Not to exceed 3.7 GBq (100 mCi) Cobalt-57
B. Any radioactive material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any radioactive material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any radioactive material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Any radioactive material identified in rule 3701:1-46-11	E. Prepackaged Kits	E. As needed
F. Yttrium-90	F. Any form	F. 4.1 GBq (110 mCi)
G. Uranium depleted in Uranium-235	G. Cadmium plated metal	G. As needed
H. Iridium-192	H. Brachytherapy Source Wire (Amersham Model LW.100)	H. Not to exceed 7.4 GBq (200 millicuries) per source wire. Total possession not to exceed 11.1 GBq (300 millicuries)

6. Authorized Use

- A. Uptake, Dilution and Excretion studies per 10 CFR 35.100, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- B. Diagnostic Imaging and Localization studies per 10 CFR 35.200, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- C. Medical use described in 10 CFR 35.300, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- D. Brachytherapy procedures per 10 CFR 35.400, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- E. In vitro studies
- F. Calibration and reference source for Yttrium-90 Zevalin use.

OHIO DEPARTMENT OF HEALTH LICENSE FOR RADIOACTIVE MATERIALS SUPPLEMENTARY SHEET	Page 2 of 4
	License Number 02120490004
	Bureau Docket Number: DC/CJC51-12-97
	Amendment No. 11

- G. Shielding in a linear accelerator.
- H For interstitial treatment of cancer.

CONDITIONS

7. Licensed material may only be used at the licensee's facilities located at:
- |   |  |   |
|---|--|---|
| Flower Hospital<br>5200 Harroun Road<br>Sylvania, Ohio 45360-2196 | Lake Park Continuing Care Facility<br>5100 Harroun Road<br>Sylvania, Ohio 45360-2196 | (diagnostic/therapeutic administration of<br>radiopharmaceuticals only) |
|---|--|---|
8. Radiation Safety Officer for this license is:  
*Joseph T. Rakowski, M.S.*
9. Licensed material shall be used by, or under the supervision of, individuals designated in writing:

<u>Authorized Users</u>	<u>Material and Use</u>
A. Michael R. Hay, M.D.	A. 10 CFR 35.100, 10 CFR 35.200, 10 CRF 35.300 and 3701:1-46-11 uses.
B. Wayne S. Court, M.D.	B. 10 CFR 35.300 and 10 CFR 35.400 uses.
C. Murray A. Howe, M.D.	C. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
C. Allan S. Kaufman, M.D.	D. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
D. Blaine A. Keigley, M.D.	E. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
E. Tamara S. Martin, M.D.	E. 10 CFR 35.100, 10 CFR 35.200, 10 CRF 35.300 and 3701:1-46-11 uses.
F. William G. Novak, M.D.	F. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
G. Parag U. Parikh, M.D.	G. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
H. David A. Parker, M.D.	H. 10 CFR 35.100, 10 CFR 35.200, 10 CRF 35.300 and 3701:1-46-11 uses.
I. Charles I. Price, M.D.	I. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
J. Thomas N. Sardelis, M.D.	J. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
K. Robin B. Shermis, M.D.	K. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
L. Phillip J. Silverman, M.D.	L. 10 CFR 35.100, 10 CFR 35.200, 10 CRF 35.300 and 3701:1-46-11 uses.
M. Daniel Singer, M.D.	M. 10 CFR 35.100, 10 CFR 35.200, 10 CRF 35.300 and 3701:1-46-11 uses.
N. Keith D. Wilson, M.D.	N. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
O. Jonathan J. Yobbagy, M.D.	O. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
P. Rajender K. Ahuja, M.D.	P. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire.
Q. Andre A. Konski, M.D.	Q. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire.

OHIO DEPARTMENT OF HEALTH LICENSE FOR RADIOACTIVE MATERIALS SUPPLEMENTARY SHEET	Page 2 of 4
	License Number 02120490004
	Bureau Docket Number: DC/CJC51-12-97
	Amendment No. 11

- |                               |   |
|-------------------------------|---|
| R. Chun H Mah, M.D.           | R. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire  |
| S. Gerald W. Marsa, M.D.      | S. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire  |
| T. William K. Mueller, M.D.   | T. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire  |
| U. Steven R. Zeidner, M.D.    | U. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire  |
| V. Robert S. Disalle, M.D.    | V. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.   |
| W. Malcom T. Doyle, M.D.      | W. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses  |
| X. Timothy J. Quinn, M.D.     | X. 10 CFR 35.100; 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses  |
| Y. Edmund P. Ho, M.D.         | Y. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire  |
| Z. Steven J. Rubin, M.D.      | Z. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire  |
| AA. Amy Culler, M.D.          | AA. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 uses  |
| BB. Steven Kumar-Jindal, M.D. | BB. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 uses  |
| CC. Susan M. Hong             | CC. 10 CFR 35.300 (excluding Iodine-131 for treatment of hyperthyroidism and thyroid carcinoma), 10 CFR 35.400 and Iridium-192 wire |
| DD. John Feldmeier, M.D.      | DD. 10 CFR 35.300 & 35.400 uses.  |
| EE. Vincent J. Keiser, M.D.   | EE. 10 CFR 35.100, 10 CFR 35.200 and 3701:1-46-11 uses  |
| FF. Ibrahim Naveed Syed, M.D. | FF. 10 CFR 35.11, 10 CFR 35.200, 10 CFR 35.300 (limited to treatment of hyperthyroidism), and 3701:1-46-11 uses                     |
| GG. Dolly Razdan, M.D.        | GG. 10 CFR 35.300 and 10 CFR 35.400 uses  |

10. All sealed sources that are used or obtained shall have been evaluated and approved under the provisions of OAC 3701:1-46-49 or by equivalent NRC, Agreement State, or NARM licensing state regulation.
11. All person performing activities meeting the definition of "Nuclear Medicine Technologist" as specified in R.C. 4773.01 shall be licensed by, and in good standing with the State of Ohio.
12. The licensee shall establish and implement a bioassay program for all individuals involved with preparation and administration of Iodine-131 therapy doses in excess of 30 millicuries. The program shall be equivalent to that outlined in Appendix P of Regulatory Guide 10.8 Revision 2.
13. Notwithstanding the provisions of 10 CFR 35.400(d), as delineated in rule 3701-39-02.1 of the Ohio Administrative Code, the licensee may use iridium-192 seeds encased in nylon ribbon as described in application dated April 20, 1992 and letter dated June 8, 1992 for intracavitary treatment of cancer.
14. The licensee shall follow the manufacturer's instructions for handling and cutting Iridium-192 brachytherapy source wires.
15. The licensee shall maintain records of information related to decommissioning at the location listed in item 2 of this license as specified in rule 3701:1-40-17(I) of the Ohio Administrative Code until this license is terminated by the Commission.
16. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of sealed source licensed materials to quantities below the minimum limit specified in rule 3701:1-40-17(C) of the Ohio Administrative Code for establishing decommissioning financial assurance.

OHIO DEPARTMENT OF HEALTH  LICENSE FOR RADIOACTIVE MATERIALS  SUPPLEMENTARY SHEET	Page 4 of 4
	License Number 02120490004
	Bureau Docket Number: DC/CJC51-12-97
	Amendment No. 11

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Ohio Department of Health's statutes, rules, and orders shall govern unless statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.


- A. Application dated June 15, 1998.
- B. Letters dated August 19, 1998; March 24, 1999; September 20, 1999; February 8, 2000; March 30, 2000; November 21, 2000; August 17, 2001 & December 4, 2001.
- C. Correspondence on USNRC license number 34-15184-01, Amendment number 40.
- D. Telefacsimile dated February 15, 2000.
- E. Letter dated March 25, 2002.
- F. Letter dated June 11, 2002.
- G. Letter dated December 30, 2002, facsimiles dated January 29, 2003 and February 18, 2003.
- H. Letter dated February 20, 2003 requesting change in RSO to Joseph Rakowski, M.S.

For the Ohio Department of Health

DATE

3/10/03

BY



Director, Ohio Department of Health

Karmanos Cancer Center  
Mail Code 6E00 R0  
4100 John R St.  
Detroit, MI 48201



U.S. POSTAGE METREY GENIES  
ZIP 48201 \$ 000.50<sup>0</sup>  
DZ 4R  
00003529 15 DEC 11 2020

U.S. Nuclear Regulatory Commission, Region III  
Materials Licensing Branch  
2443 Warrenville Road, Suite 210  
Lisle, IL 60532-4352

RECEIVED JAN 05 2021

6053224352 0021

